Eyes on GLP-1 receptor agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists, such tirzepatide and semaglutide, have evolved from specialised diabetes treatments to household brands in recent years. The UK's approach to obesity and type 2 diabetes has changed as a result of its powerful effects on appetite suppression, weight loss, and glycaemic management, with prescriptions increasing in both private clinics and NHS services. Although metabolic and cardiovascular benefits have received most of the emphasis in public and professional discourse, another organ system deserves further consideration: the eyes. Understanding GLP-1 receptor agonists' possible ocular effects- both positive and negative - is becoming more crucial as their use rises.